{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-078927","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.248498+00:00","generated_at":"2026-06-10T09:18:25.954319+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jasper Therapeutics appoints Herb Cross as CFO; Jeet Mahal continues as COO","bullets":["Herb Cross, age 51, appointed CFO and Corporate Secretary effective Sept 22, 2023; prior CFO at Atreca.","Cross receives $460k base salary, 45% annual bonus target, $100k sign-on bonus.","Granted option to purchase 550,000 shares at $0.78/share; vests over 4 years (25% cliff at 1 yr, then monthly).","Jeet Mahal transitions from dual CFO/COO role to solely COO.","Option is an inducement grant under Nasdaq Listing Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-078927","json":"https://secwatch.observer/filing/0001213900-23-078927.json","markdown":"https://secwatch.observer/filing/0001213900-23-078927.md","text":"https://secwatch.observer/filing/0001213900-23-078927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/0001213900-23-078927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/ea185698-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T09:18:25.954319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26703727b4","claim":"Herb Cross was appointed as Chief Financial Officer and Corporate Secretary at Jasper Therapeutics, Inc..","evidence_excerpt":"On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51 , as its Chief Financial Officer and Corporate Secretary.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/0001213900-23-078927-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Corporate Secretary"}],"fact_type":"executive_change"},{"claim_id":"b0b21a0acb","claim":"Jeet Mahal changed role as Chief Operating Officer at Jasper Therapeutics, Inc..","evidence_excerpt":"the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023078927/0001213900-23-078927-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned to solely COO"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}